CRANBURY, N.J., May 12, 2011 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) will host a conference call and webcast on May 16, 2011 at 11:00 a.m. Eastern Time to discuss its quarter ended March 31, 2011 financial results and its programs, focusing on the upcoming start of its Phase 2 clinical trial with bremelanotide for women with female sexual dysfunction. Schedule for the Financial Results Press Release, Conference Call / WebcastQ3 Fiscal Year 2011 Conference Call-Live
5/16/2011 at 11:00 a.m. ETDomestic Dial-In Number
1-866-316-1363International Dial-In Number
2950108Q3 Fiscal Year 2011 Conference Call-Replay
5/16-5/23/2011Domestic Dial-In Number
1-888-203-1112International Dial-In Number
2950108Webcast Live and Replay Access
http://www.palatin.comThe webcast and replay can be accessed by logging on to the “Investor/Media Center-Webcasts” section of Palatin’s website at http://www.palatin.comAbout Palatin Technologies, Inc.Palatin Technologies, Inc. is a biopharmaceutical company dedicated to the development of peptide, peptide mimetic and small molecule agonists with a focus on melanocortin and natriuretic peptide receptor systems. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential. For additional information regarding Palatin, please visit Palatin Technologies' website at www.palatin.com.
|SOURCE Palatin Technologies, Inc.|
Copyright©2010 PR Newswire.
All rights reserved